Relmada Therapeutics, Inc. RLMD Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$57.39M+28.3% | -$79.98M+19.0% | -$98.79M+37.1% | -$157.04M-24.9% | ||
| $13.91M-53.9% | $30.18M-31.1% | $43.81M-0.9% | $44.19M+9.1% | ||
| —— | —— | —— | $421.04K— | ||
| —— | —— | $1.48M— | —— | ||
| —— | —— | —— | —— | ||
| $398.25K— | —— | $3.82M+191% | -$4.22M-590% | ||
| -$45.79M+11.5% | -$51.76M-0.2% | -$51.66M+50.2% | -$103.8M-13.0% | ||
| $83.83M+594% | $12.08M-86.6% | $90.46M+91.3% | $47.29M-78.8% | ||
| $35.69M-43.9% | $63.64M-54.8% | $140.92M+110% | $67.03M-60.3% | ||
| $26.88M-41.8% | $46.18M-15.7% | $54.81M-51.6% | $113.32M+25.1% | ||
| -$48.14M-193% | $51.56M-0.1% | $51.61M+141% | $21.39M+140% | ||
| —— | —— | —— | —— | ||
| $93.64M+37,849% | $246.75K— | —— | $42.78M-76.8% | ||
| —— | —— | -$98.46K-100% | $45.02M-76.0% | ||
| —— | —— | —— | —— | ||
| $14.81M-50.9% | $30.18M-31.1% | $43.81M-0.9% | $44.19M+9.1% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| -$79.21K-121% | $374.93K+109% | -$4.06M-594% | -$585.52K+7.9% | ||
| —— | —— | —— | —— | ||
| —— | $4.47K— | —— | —— | ||
| —— | —— | —— | —— | ||
| $83.83M+594% | $12.08M-86.6% | $90.46M+91.3% | $47.29M— | ||
| $35.69M-43.9% | $63.64M-54.8% | $140.92M+110% | $67.03M-60.3% | ||
| $73.02K-74.6% | $287.09K+192% | $98.46K— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $32.22M-14.6% | $37.72M-22.9% | $48.89M+2.0% | $47.93M+36.6% | ||
| $1.4M-60.5% | $3.53M-31.5% | $5.15M— | —— | ||
| $1.72M-56.2% | $3.91M-20.3% | $4.91M+16.8% | $4.21M+8,803% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | -$98.46K— | —— | ||
| $398.25K— | —— | $3.82M+191% | -$4.22M-590% | ||
| —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Relmada Therapeutics, Inc. generate?
- Relmada Therapeutics, Inc. (RLMD) generated -$42.8M in operating cash flow over the trailing twelve months.
- What is Relmada Therapeutics, Inc.'s free cash flow?
- After $182.1M of capital expenditures, Relmada Therapeutics, Inc.'s free cash flow was -$209.9M over the trailing twelve months, down 116.5% year over year.
- Where does Relmada Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Relmada Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.